Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

2019220 citationsJournal Articlehybrid Open Access

Authors

Cristina Müller · Paul Scherrer Institute

Christoph A. Umbricht · Paul Scherrer Institute

Nadezda Gracheva · Paul Scherrer Institute

Viviane J. Tschan · Paul Scherrer Institute

Giovanni Pellegrini · University of Zurich

Peter Bernhardt · University of Gothenburg

Jan Rijn Zeevaart

Abstract

161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161Tb-PSMA-617 for the treatment of mCRPC.

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research Medical Imaging and Pathology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Volume 46, Issue 9, pp. 1919-1930

DOI: 10.1007/s00259-019-04345-0

Field-Weighted Citation Impact: 14.42